Biography
Assistant Professor Sutima Luangdilok is a board-certified medical oncologist and obtained her PhD from the Institute of Cancer Research: Royal Cancer Hospital, University of London. She graduated with first class honor and complete her medical oncology residency training from Faculty of Medicine Siriraj Hospital, Mahidol University. Currently, she teaches medical students at Faculty of Medicine, Chulalongkorn University and treats cancer patients at King Chulalongkorn Memorial Hospital. Her interest is in precision oncology which integrates understanding of cancer biology to design the most suitable therapies for individual cancer patients.
Education
- 2010-2014 Medical Oncology, Division of Medical Oncology, Faculty of Medicine Siriraj Hospital
- 2007-2010 MD (First Class Honors), Faculty of Medicine Siriraj Hospital, Mahidol University
- 2003-2007 PhD, the Institute of Cancer Research: Royal Cancer Hospital, University of London, UK
- 1998-2002 BSc (Medical Science) (First Class Honors), Faculty of Medicine Siriraj Hospital, Mahidol University
Certifications and licensures
- 2014 Diplomat, Thai Board of Medical Oncology
- 2011 Certificate of Postgraduate Clinical Medical Sciences, Mahidol University, Thailand
- 2010 Certificate of Medical Licensure, Thailand
Awards
2015 International Oncology Leading Investigator Training Program, AstraZeneca
2014 International Development and Education Award from Conquer Cancer Foundation of the American Society of Clinical Oncology
2003 PhD scholarship from The Head and Neck Cancer Research Trust, UK
2001 Medical scholars program, Mahidol University
- 2000 Scholarship award for highest score in Clinical Pathology, Faculty of Medicine Siriraj Hospital
- 1996 Scholarship award for highest score in Mathematics, Triam Udom Suksa School
Publications
- Akkhasutthikun, P. Kaewsapsak, P. Nimsamer, P. Klomkliew, P. Visedthorn, S. Chanchaem, P. Teerapakpinyo, C. Payungporn, S. Luangdilok, S. Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer. Cancer Res Treat. 2024;56(2):455-63.
- Luangdilok S, Wanchaijiraboon P, Poonchavist Chantranuwatana, Chinachote Teerapakpinyo, Shanop Shuangshoti, Virote Sriuranpong (2019) Cyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer. Translational Lung Cancer Research 8 (6), 959–966.
- Luangdilok, S., Samarnthai, N., and Korphaisarn, K. (2014). Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. J Breast Cancer 17, 376-385.
- Teeyapun N, Luangdilok S, Pakvisal N, et al. Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study. eClinicalMedicine 2022; 52: 101608.
- Luangdilok S, Wanchaijiraboon P, Pakvisal N, et al. Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine. Vaccines 2022;10(10):1613.
Books
- สุทิมา เหลืองดิลก ชีววิทยาของมะเร็งปอด ใน วิโรจน์ ศรีอุฬารพงศ์, บรรณาธิการ มะเร็งปอด (LUNG CANCER), e-book ศูนย์หนังสือแห่งจุฬาลงกรณ์มหาวิทยาลัย พ.ศ. 2561 หน้า 1-11